Clinical Trials Logo

Postmenopausal Osteoporosis clinical trials

View clinical trials related to Postmenopausal Osteoporosis.

Filter by:

NCT ID: NCT00092027 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

Start date: March 19, 2003
Phase: Phase 3
Study type: Interventional

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

NCT ID: NCT00092014 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

FACT
Start date: September 1, 2002
Phase: Phase 3
Study type: Interventional

This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.

NCT ID: NCT00091793 Completed - Clinical trials for Postmenopausal Osteoporosis

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Start date: August 2004
Phase: Phase 3
Study type: Interventional

This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

NCT ID: NCT00086619 Completed - Osteoporosis Clinical Trials

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

Start date: May 2004
Phase: Phase 2
Study type: Interventional

Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains its ability to improve bone formation, and optional sub-studies will test several potential reasons why PTH's effects on bone formation decline over time.

NCT ID: NCT00079924 Completed - Clinical trials for Postmenopausal Osteoporosis

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Start date: November 2004
Phase: Phase 4
Study type: Interventional

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.